Rustin G J
Department of Medical Oncology, Charing Cross Hospital, London.
Dis Markers. 1991 May-Aug;9(3-4):153-8.
The clinical value of serum CA 125 in the management of patients with ovarian carcinoma has now been proven. Its role in screening for early potentially curable disease remains unproven due to its low sensitivity for early disease and requires further study in clinical trials. Its use in diagnosis of malignant pelvic lesions could lead to a more appropriate operation. Its most useful present application is to indicate which patients are no longer responding to chemotherapy and to prevent them being given unnecessary unpleasant treatment and also to avoid other investigations such as CT scans which give less information. Definitions for response to a specific therapy and also progression according to CA 125 criteria are given and require prospective testing.
血清CA 125在卵巢癌患者管理中的临床价值现已得到证实。由于其对早期疾病的敏感性较低，其在筛查早期可能治愈疾病方面的作用仍未得到证实，需要在临床试验中进一步研究。其在恶性盆腔病变诊断中的应用可导致更合适的手术。其目前最有用的应用是指出哪些患者对化疗不再有反应，防止他们接受不必要的不良治疗，并避免进行其他提供信息较少的检查，如CT扫描。给出了根据CA 125标准对特定治疗的反应以及进展的定义，需要进行前瞻性测试。
